19Dec
As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which awaits approval by shareholders and regulators, is the largest purchase by a health care company this year and is expected to close in the third quarter of 2021. Alexion was founded in 1992 and is headquartered in Boston but has a global presence. It is known for its...
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On June 17th the Department of Labor finalized a set of proposed regulations requiring that all “to...
Read More >
In 2018, in response to the #MeToo and #TimesUp movements, New York State enacted laws to provide st...
Read More >
Seyfarth synopsis: Arkansas has sought certiorari on the question of the ability of states under the...
Read More >
Shifting demographics threaten the ability of construction companies to staff projects. Many industr...
Read More >
Did I do that? Happy new year, everybody! Greg Giangrande of the New York Post's @Work column answ...
Read More >
Just in time for the holidays, Congress gave plan sponsors and employee benefits attorneys a reason ...
Read More >